KPV

KPV (Lys-Pro-Val) is a three-amino-acid peptide cut from the tail of alpha-melanocyte-stimulating hormone (α-MSH), a hormone that helps control inflammation, fever, and skin pigment. It is the final segment of α-MSH (positions 11-13), and it holds on to the parent hormone's anti-inflammatory and fever-reducing activity while leaving behind its pigment-stimulating effects ¹.

The peptide's function was first recognized in 1984, when structure-activity studies singled out the C-terminal Lys-Pro-Val sequence as pharmacologically important ²⁰, and isolated KPV reduced fever in rabbits ¹⁵. Later work showed how it reaches inflamed tissue: an intestinal transporter called PepT1, which is more active in inflamed colon, carries the peptide into the gut wall ⁹.

Research has clustered around a few indications:

• Inflammatory bowel disease and colitis. The strongest and most replicated area. Oral KPV reduced colitis severity in mouse models ⁸, and engineered carriers improved outcomes further ¹⁰.
• Skin inflammation and wound repair. KPV protects skin cells from oxidative and pollutant stress and supports regeneration in wound models ⁴.
• Metabolic health. Recent work in obese mice and in fat and liver cell models suggests KPV limits weight gain and lipid accumulation ⁵.
• Early-stage targets. Vascular calcification ¹⁷, colitis-associated cancer ¹⁶, and vitiligo repigmentation ¹⁸.

No human trials of KPV exist. Every finding above comes from cells, animal models, or ex vivo human skin, so dosing, safety, and effect size in people remain uncharacterized ¹⁹.

KPV works by damping inflammation inside cells. Its main target is nuclear factor-kappa B (NF-κB), a master switch that turns on inflammatory cytokine genes. KPV blocks NF-κB activation triggered by a range of inflammatory signals, and at the same time prompts cells to release interleukin-10 (IL-10), an anti-inflammatory cytokine ¹.

In inflamed intestinal cells, KPV reduced NF-κB activation, blunted the stress-kinase signals ERK1/2, JNK, and p38, and lowered secretion of the inflammatory signaling molecule IL-8 ²¹. In human skin cells exposed to a pollutant, KPV suppressed NF-κB downstream of oxidative stress, reduced IL-1β release, and dialed back pro-cell-death proteins ⁴.

How it reaches its target

KPV is actively carried into cells by PepT1, a transporter for small peptides ²¹. Because PepT1 is overexpressed in inflamed colon tissue, KPV concentrates where the gut is damaged ⁹. In lab cell layers, KPV competed for about half of this transporter's capacity, a signature of proton-coupled peptide transport ²¹.

KPV also binds the melanocortin-1 receptor (MC1R), a receptor involved in skin pigmentation. That engagement activates a signaling chain (cAMP-tyrosinase) that raises melanin production, which is how KPV-modified liposomes promoted repigmentation in a mouse model of vitiligo ¹⁸. In airway cells, KPV's anti-inflammatory effect runs through the related melanocortin-3 receptor ²⁵.

Other contributing actions

• ROS quenching. KPV lowers reactive oxygen species (ROS), oxidative molecules that feed inflammatory signaling, and blocks a form of inflammatory cell death called pyroptosis ⁴.
• Lipogenesis suppression. In fat and liver cells, KPV suppresses the AKT/mTORC1/PPARγ axis, which in turn reduces fatty acid synthase and lipid accumulation ⁵.
• Antimicrobial activity. KPV shows direct antimicrobial activity in vitro, and KPV-loaded hydrogels combat MRSA in wound models ³.

KPV's documented effects come entirely from preclinical work: cell lines, animal models, and ex vivo human skin. No human efficacy data exist ¹⁹.

Gut inflammation

The strongest and most replicated findings. Free oral KPV reduced disease severity in a mouse model of colitis ²¹, and later studies confirmed anti-inflammatory activity across several murine colitis models ⁸. Engineered carriers improved on this: hyaluronic acid-coated nanoparticles accelerated mucosal healing and lowered TNF-α in mice with ulcerative-colitis-like disease, outperforming plain KPV ¹⁰. A prodrug designed to release only at sites of inflammation matched free KPV's effect at a 20-fold lower dose ¹¹. KPV also showed a therapeutic benefit in a mouse model of colitis-associated cancer ¹⁶.

Skin and wound repair

In human keratinocyte cultures exposed to a fine-dust pollutant, KPV at 50 mcg/mL reduced oxidative stress, blocked inflammatory cell death (pyroptosis), and restored cell viability, with the effect repeated in a 3D skin model ⁴. KPV-loaded hydrogels reduced inflammation, promoted tissue regeneration, and showed anti-MRSA activity in wound models ¹². Iontophoresis, which uses a mild electric current, carried KPV across microporated human skin ex vivo ¹³.

Metabolism

In high-fat-diet mice, oral KPV blunted body-weight gain, white-fat expansion, liver-mass increase, and plasma cholesterol ¹⁴. In cell models, KPV suppressed fat-cell maturation and hepatic lipid accumulation without cytotoxicity ⁵. These metabolic findings are recent and await independent replication.

Other findings

• Fever. KPV, the α-MSH 11-13 fragment, reduced fever in rabbits in 1984 work ¹⁵.
• Vascular calcification. Self-assembled KPV-rapamycin nanoparticles inhibited vascular calcification in mice ¹⁷.
• Pigmentation. KPV-modified liposomes promoted repigmentation in a mouse vitiligo model via MC1R ¹⁸.

No human clinical trials of KPV exist, so every published protocol is preclinical. Animal studies used oral dosing daily for days in acute colitis models ²¹ and for weeks in diet-induced obesity studies ¹⁴. Delivery studies relied on engineered carriers because plain oral KPV survives the gastrointestinal tract poorly ¹⁰. The timeline below reflects the subcutaneous pattern most often described in community practice.

Human-dose figures in circulation come from community and practitioner practice, not trials. Community protocols typically use 200-500 mcg daily by subcutaneous injection, or 500-1,000 mcg orally, for 4-8 week cycles. Some practitioners scale dosing to body weight at roughly 3-7 mcg/kg, but no human data validate any dose or weight-based adjustment.

Route choice follows the target. Oral KPV suits gut and mucosal indications because PepT1 concentrates it in inflamed colon tissue ⁹, although plain oral peptide degrades in the GI tract, which is why later animal studies used encapsulated or prodrug forms ¹⁰. Subcutaneous administration is the predominant injectable route in community practice and avoids GI degradation. Topical hydrogels are used for surface lesions, with transdermal iontophoresis demonstrated across human skin ex vivo ¹³.

No human chronobiology data exists. Community practice sometimes splits the daily subcutaneous dose morning and evening for steady anti-inflammatory coverage, and takes oral doses fasted or between meals because dietary peptides are thought to compete for the PepT1 transporter.

Community protocols typically cycle for 4-8 weeks, then pause 1-4 weeks before resuming; longer courses are reported for chronic inflammatory bowel conditions. No human tolerance, rebound, or withdrawal data exist.

KPV is supplied as a lyophilized (freeze-dried) powder. The standard diluent in practice is bacteriostatic water, which contains 0.9% benzyl alcohol to limit bacterial growth. Saline-based reconstitution is discouraged when the solution will be stored for multiple weeks.

To mix, add the diluent slowly down the vial wall and roll the vial gently until the powder dissolves. Do not shake or vortex, which can damage the peptide. A properly mixed solution is clear and colorless; discard anything cloudy or particulate.

Storage follows standard freeze-dried peptide handling. Keep the dry powder at -20°C for long-term storage (2+ years); 2-8°C is fine for short-term storage and shipping, protected from light and moisture. Once reconstituted, keep the solution refrigerated at 2-8°C and use it within about 30 days. Do not refreeze reconstituted solutions; freeze-thaw cycles accelerate breakdown.

Stability deserves attention with KPV. The tripeptide degrades in water under acid, alkali, and oxidative stress, with lys-Pro-diketopiperazine as the main breakdown product ²². A validated lab assay can measure KPV down to 0.01 mcg/mL, so third-party testing is possible for compounded material ²². The calculator below works out volume-per-dose figures for a given vial size, diluent volume, and dose.

No human drug-interaction studies exist for KPV; combination data are preclinical. The following categories come from co-delivery studies and mechanistic overlap.

• PepT1 substrate drugs. KPV is actively transported by PepT1 and competes for roughly half of its uptake capacity in intestinal cell layers ²¹. Beta-lactam antibiotics, ACE inhibitors such as captopril and enalapril, valacyclovir, and 5-aminolevulinic acid share this transporter, so high-dose oral KPV could theoretically compete for intestinal absorption. Conversely, PepT1 upregulation in inflamed colon is exactly how KPV reaches damaged tissue, so this is a double-edged mechanism rather than a simple conflict.
• mTOR inhibitors (rapamycin). KPV and rapamycin co-assembled into nanoparticles that suppressed vascular calcification in mice better than either agent alone ¹⁷. KPV also lowers AKT/mTORC1 signaling on its own in cell models, so the combination is mechanistically additive ⁵.
• Calcineurin inhibitors (cyclosporine). KPV and cyclosporine were co-delivered in nanoparticles for colitis in mice, with the KPV-only arm also markedly improving disease, suggesting additive rather than antagonistic effects ²⁴.
• Corticosteroids. Co-loaded in KPV-modified liposomes for vitiligo in mice, steroid and KPV worked through complementary pathways, with no interference documented ¹⁸.
• Aminosalicylates (5-ASA). Co-encapsulation in microspheres preserved the anti-inflammatory activity of both agents in colonic cell assays ²⁶.
• Melanocortin ligands. KPV engages MC1R ¹⁸, so combining with melanotan II or similar agents is theoretically redundant for pigmentation; the KPV motif also shifts melanocortin receptor selectivity when engineered into larger peptides ⁷.

Supplements

• Antioxidants. Vitamin C and NAC plausibly add to KPV's cell-protective effects, but should not be mixed with KPV in the same vial because oxidative conditions degrade the peptide ²².
• Fish oil and polyphenols. Omega-3s, curcumin, resveratrol, and quercetin share NF-κB and antioxidant targets, so effects are likely additive or redundant; no antagonism is documented.

KPV is commonly combined with other repair and anti-inflammatory peptides in community protocols. The rationale is mechanistic complementarity: KPV contributes NF-κB anti-inflammatory activity, which sits alongside partners with different jobs.

• BPC-157. The most frequently paired companion for gut repair. A 2026 comparative review positions BPC-157 as primarily angiogenic (promoting new blood vessel growth) and vascular-protective, while KPV's profile is anti-inflammatory via NF-κB modulation ⁶. Community protocols frequently stack the two for gut healing; no co-study data exists.
• TB-500 / thymosin beta-4. TB4 drives actin-mediated cell migration and tissue remodeling ⁶. KPV adds anti-inflammatory and antimicrobial activity ³. The mechanisms are distinct, so no conflict is expected.
• GLP-1 agonists (semaglutide and related). KPV's anti-lipogenic and cholesterol-lowering effects in obese mice suggest theoretical metabolic additivity ¹⁴. No human or co-administration data exist.
• Melanotan II and α-MSH analogs. Both engage melanocortin receptors; combination is redundant for pigmentation and raises theoretical receptor-competition concerns ⁷.
• GH secretagogues (ipamorelin, CJC-1295). No direct interaction evidence; multi-peptide protocols sourced from unregulated supply chains carry undefined longer-term metabolic and cardiovascular risk ¹⁹.

KPV is not FDA-approved for any indication, and it holds no marketing authorization from the EMA (EU), TGA (Australia), or MHRA (UK). It is not a controlled substance; as an endogenous α-MSH fragment it sits outside DEA scheduling frameworks. In US practice, KPV has been obtained through compounding pharmacies preparing patient-specific prescriptions, though it is not on the FDA-approved bulk drug substance list. No KPV-specific FDA warning letter or enforcement action is documented; the literature instead flags systemic mislabeling and contamination risk across the peptide market ¹⁹.

The evidence base is exclusively preclinical, and a 2026 comparative review concluded that clinical consolidation depends on controlled studies that have not yet been performed ⁶.

In sport, KPV falls under WADA Prohibited List category S0 (non-approved substances), which is prohibited at all times, in and out of competition. Because S0 substances lack governmental approval for human therapeutic use, no therapeutic use exemption (TUE) is available. Detection is complicated by short peptide half-lives and structural similarity to endogenous hormones, which narrows the testing window ¹⁹. A 2026 review characterized peptide use in competitive and recreational sport as high-risk until longitudinal safety and prevalence data emerge ¹⁹.

No human safety data exist for KPV; the profile is built from preclinical signals and community reports. Across the literature, KPV is repeatedly described as non-toxic at studied concentrations. Nanoformulations were characterized as nontoxic and biocompatible with intestinal cells ¹⁰, and cell viability was maintained or restored at 50-100 mcg/mL in skin, liver, and fat cell models ⁴. Animal colitis, obesity, and vascular studies reported efficacy without treatment-attributable adverse events ¹⁴.

Community reports for injectable use (typically 100-300 mcg daily) are mild and transient: redness, itching, or a small wheal at the injection site that resolves in minutes to hours. Many users report no perceptible effects at all.

Theoretical considerations

• Pigmentation. KPV binds MC1R and can increase melanin production in the right context ¹⁸, so prolonged topical or mucosal use carries a theoretical hyperpigmentation risk, though the free tripeptide itself lacks classical pigment-stimulating activity ³.
• Immune effects. Sustained NF-κB suppression could theoretically blunt the response to an active infection; KPV's own in-vitro antimicrobial activity partially offsets this concern ³.
• Transport interference. Competition for PepT1 could theoretically alter the absorption of drugs that share the transporter, but no interaction studies exist ²¹.
• Cancer. PepT1 is overexpressed in colorectal cancer and KPV concentrates in PepT1-expressing tumors ¹⁶. The direction of effect is unclear: KPV showed therapeutic benefit in a colitis-associated cancer model, but the net effect on established malignancy is unknown ¹⁶.

What remains unknown is substantial: human pharmacokinetics, subcutaneous-route safety, long-term exposure, drug interactions, and any safe upper dose ¹⁹. Practitioner consensus treats pregnancy and breastfeeding as contraindications because no reproductive safety data exist, and documented hypersensitivity is the only hard contraindication.